|By PR Newswire||
|February 17, 2014 07:37 AM EST||
LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Emerging Technology and Major Partnerships in Influenza Vaccines
Influenza is a burgeoning problem across the entire globe, there is an increased need for new therapeutic methods. A whole host of technology platforms are being utilized to create non egg based vaccines. The world has not seen an influenza pandemic, and in terms of historical occurrences, we are several years overdue of one. There is a critical need for a universal vaccine, that has the potential to prevent multiple strains of influenza, so that yearly vaccinations can be eliminated and healthcare costs can be reduced. The main focus of the research service features the influenza vaccine market and the types of emerging technologies as well as developing partnerships over 2010-2013.
1. The Influenza therapeutics industry can be split into two main segments the antiviral industry and the influenza vaccines industry. There is a lot of funding for these industries to ensure protection for the global population against seasonal and pandemic influenza. Companies are striving to cover everyone, including the high-risk groups, such as children below the age of 2, adults above the age of 65, and people with preexisting medical conditions.
2. The influenza vaccine industry is witnessing a shift from the conventional egg-based vaccine development methods to more novel approaches. Some of them being DNA-based, recombinant subunit-based and even microbial vector-based approaches. These approaches are proving to be more cost effective and seem to have a higher rate of mass production, which is crucial if an influenza pandemic surfaces.
3. Efforts are being directed toward covering a boarder spectrum of viral strains than those presently being covered by seasonal influenza vaccines. The FDA has approved quadrivalent vaccines for distribution during the 2013-2014 seasonal influenza which covers Xstrains. There has been an increase in collaborations for the development of these 'universal vaccines' across the globe.
4. Developing new modes of administration of influenza vaccines is also an avenue that is being heavily explored by large and small biotechnology companies. They aim to eliminate the need for a needle and make it less invasive; this seems to be the primary focus of most research efforts. Some of the more nascent forms of administrating vaccines are oral vaccines and vaccine patches.
5. Looking more into R&D in a geographic perspective, there is a lot of funding going into influenza therapeutics in the US. In Europe, there is greater focus of R&D on new antiviral drug therapies and less focus on the vaccine industry. There is increasing focus on R&D in Asia Pacific and various new developments have taken place on the vaccine front, especially in countries, such as Singapore and Australia.
Influenza is a form of viral infection that can spread rapidly between people. It affects almost every age group and tends to impact the economy due to a significant decrease in productivity when employed professionals take sick leave. Seasonal epidemics usually affect the northern hemisphere (temperate regions) during the winter months. According to the Centers for Disease Control (CDC), worldwide influenza affects about Xmillion people annually and causes anywhere between X to Xdeaths. Children below the age of two, senior citizens ( over 65 years) and people who already have medical aliments, fall under the high-risk group. Seasonal influenza can be prevented by annual vaccinations against the prevalent strains for that season.
Influenza strains tend to rapidly mutate, aiding them in gaining resistance against the influenza vaccinations and antiviral drugs. Scientists in university laboratories and pharmaceuticals are trying to develop universal vaccines, that will provide patients boarder coverage against multiple influenza strains.
Looking at the larger picture, the influenza therapeutics industry has been experiencing many crucial changes. There are quite a few technical and business challenges that require immediate attention. The healthcare industry in general is moving toward preventative treatment options. Vaccine improvements will benefit all age groups as well as people with pre-existing conditions. The target demographics for these vaccines will increase , subsequently reducing epidemics across the globe.
Referencing sources on previous pandemics that have occurred, an influenza pandemic is currently overdue, which is an important point to note, as challenges with regards to pandemic influenza vaccinations need to be addressed immediately, to stay abreast with the situation of a potential pandemic.
The research service covers the following:
• Captures technologies used for influenza therapeutics and highlights innovations in the influenza vaccines and antiviral industry Orientation of research for existing and emerging diseases.
• Outlines the research portfolio, key trends and addresses the key technical challenges and key market challenges, and key performance
• Identifies opportunities in the field of targeted drug delivery for emerging and existing applications
• Provides strategic insights by highlighting the key performance indicators in the influenza therapeutics industry
• Highlights partnerships/collaborations at a global level for enhancing the development of influenza vaccines and entering into the market
• Provides strategic recommendations and conclusions, for companies working on influenza therapeutics to identify areas of growth
• Analytical Hierarchy Process (AHP) that analyzes the current research portfolio adopted by most companies for existing and emerging diseases.
Influenza Therapeutics Snapshot
• The influenza therapeutics market is valued at more than US $6 billion. (Frost & Sullivan Research Services)
• The Influenza vaccines segment is the largest and is expected to be $X billion
• The market is dominated by prophylactic vaccines for seasonal influenza treatments.
• Trivalent intramuscular vaccines form the largest market share under prophylactic vaccines.
• It is projected that quadrivalent vaccines will start dominating the market over the next five to seven years.
Influenza Therapeutics Market
Influenza Vaccines: X%
Antiviral Drugs: X%
Presently influenza vaccines are based of two forms. One is the inactivated form that is usually delivered as an injection and the live attenuated form, that is delivered intranasally. The inactivated form can be further spilt into X different segments--the whole virus vaccine, split virus vaccine, and the subunit vaccine. These conventional methods predominantly use an egg-based production methodology. The present technology trend is moving toward reducing the egg-based production approach and delving deeper into cell-based production approaches.
The cell-based approaches are still under development and do not have any standardized protocols. There is also a lot of government, and private funded research taking place in small biotechnology companies and universities that are focusing on innovating novel technology platforms to produce and manufacture influenza vaccines. The conventional methods of production are not cost effective and take a long time to produce, approximately 6 to 9 months is needed for a flu vaccine to become available to the end user population. These novel and nascent technologies are aimed at solving challenges involving high cost of production and reduce the time required for the vaccine to become available to the end users.
• Influenza, commonly known as 'flu' is a respiratory infection caused by RNA viruses in the Orthomxyoviridae family.
• It is divided into three subtypes A, B and C, based on antigenic and genetic differences in their hemagglutinin (HA) and neuraminidase (NA) glycoproteins present on the surface of the virus.
• Seasonal human influenza is caused by types A and B, whereas type C occurs rarely as a mild disease in children
• Currently, the H1N1, H3N2, H5N1 strains of influenza are prevalent in humans and extensive research is being undertaken for developing therapeutics against these strains.
Influenza Subtype A
• Most of the common influenza epidemics affecting the human population are predominantly caused by this particular subtype of influenza. They are constantly mutating due to antigenic shifts. Two very important proteins that are present on the viral surface are hemagglutinin (HA) and neuraminidase (NA). At present, there are around X different subtypes of HA and 9 forms of NA. This form of influenza tends to undergo both the antigenic drift as well as the antigenic shift.
Influenza Subtype B
• This genus of virus, tends to mutate at a much slower rate than the influenza virus A. But unfortunately, most vaccinations do not give lasting immunity for this strain due to the manner in which they mutate.
• Mutations also happen due to antigenic shifts similar to Influenza virus A . This genus is found only in humans unlike Influenza virus A.
Influenza Subtype C
• This is a lot rarer compare to influenza virus A & B, but it has also been known to cause some epidemics which can be severe in intensity.
Table of Contents
Executive Summary 4
•Key Findings 5
•Research Scope 6
•Segmentation of Influenza Therapeutics 7
•Influenza Therapeutics Snapshot 8
Technology Snapshot 9
•Influenza Overview 10
Strategic Assessment of Industry Environment 11
•R& D Portfolio Analysis - Vaccines 12
• By Technology 13
• By Mode of Administration 19
•R& D Portfolio Analysis - Antivirals 20
•By Technology 21
•Industry Value Chain 22
•Stakeholder Overview 23
•Industry Participants -- By Technology 25
•Research Orientation 28
•Geographic Overview 30
Partnership & Alliances 32
R&D Budgetary Analysis 40
Environmental Analysis 48
•Technology Challenges 50
•Market Challenges 53
Strategic Evaluation of Research and Development Portfolio 57
•AHP – Analytical Hierarchy Process Based Tree 58
Contacts, Patents & DSD Tables 65
The Frost & Sullivan Story 81
Read the full report:
Developments and Trends in Influenza Therapeutics (Technical Insights)
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Aug. 25, 2016 09:15 AM EDT Reads: 549
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Aug. 25, 2016 09:00 AM EDT Reads: 449
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Aug. 25, 2016 09:00 AM EDT Reads: 536
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Aug. 25, 2016 09:00 AM EDT Reads: 3,861
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Aug. 25, 2016 08:45 AM EDT Reads: 2,104
Pulzze Systems was happy to participate in such a premier event and thankful to be receiving the winning investment and global network support from G-Startup Worldwide. It is an exciting time for Pulzze to showcase the effectiveness of innovative technologies and enable them to make the world smarter and better. The reputable contest is held to identify promising startups around the globe that are assured to change the world through their innovative products and disruptive technologies. There w...
Aug. 25, 2016 08:30 AM EDT Reads: 400
Is the ongoing quest for agility in the data center forcing you to evaluate how to be a part of infrastructure automation efforts? As organizations evolve toward bimodal IT operations, they are embracing new service delivery models and leveraging virtualization to increase infrastructure agility. Therefore, the network must evolve in parallel to become equally agile. Read this essential piece of Gartner research for recommendations on achieving greater agility.
Aug. 25, 2016 08:30 AM EDT Reads: 518
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Aug. 25, 2016 08:30 AM EDT Reads: 1,689
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
Aug. 25, 2016 08:15 AM EDT Reads: 1,480
Enterprises have forever faced challenges surrounding the sharing of their intellectual property. Emerging cloud adoption has made it more compelling for enterprises to digitize their content, making them available over a wide variety of devices across the Internet. In his session at 19th Cloud Expo, Santosh Ahuja, Director of Architecture at Impiger Technologies, will introduce various mechanisms provided by cloud service providers today to manage and share digital content in a secure manner....
Aug. 25, 2016 08:00 AM EDT Reads: 498
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
Aug. 25, 2016 07:15 AM EDT Reads: 1,871
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Aug. 25, 2016 06:30 AM EDT Reads: 1,828
Akana has announced the availability of version 8 of its API Management solution. The Akana Platform provides an end-to-end API Management solution for designing, implementing, securing, managing, monitoring, and publishing APIs. It is available as a SaaS platform, on-premises, and as a hybrid deployment. Version 8 introduces a lot of new functionality, all aimed at offering customers the richest API Management capabilities in a way that is easier than ever for API and app developers to use.
Aug. 25, 2016 06:00 AM EDT Reads: 1,421
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 25, 2016 03:30 AM EDT Reads: 2,129
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Aug. 25, 2016 02:30 AM EDT Reads: 2,154